ApiFix Ltd. announces that the company’s ApiFix system has now been used to correct scoliosis in 50 adolescents since the system was approved for marketing in Europe on June 15, 2015. ApiFix is a commercial-stage company that has developed the CE-marked ApiFix System, a non-fusion minimally invasive treatment alternative for Adolescent Idiopathic Scoliosis.
“There is a clear and urgent need for an alternative to today’s standard for scoliosis correction in adolescents 12 to 18 years old, the age when rapid growth typically occurs,” said Uri Arnin, CEO of ApiFix. “In 80% of these children, the cause of their scoliosis is ‘idiopathic,’ or unknown. While the reduction in spine mobility is certainly a difficult consequence of long spinal fusions, which are the gold standard of treating scoliosis today, other critically important negative consequences include high chance for back pain and additional spine surgery during the first 20 years post-original surgery.”
A clinical study of the ApiFix System published this year in the peer-reviewed medical journal, Scoliosis, concluded that “there are many drawbacks to the current gold standard of AIS surgery, which are almost nonexistent with the use of ApiFix: considerable blood loss leading to blood transfusions, neurologic deficit including spinal cord lesions, late infections, pseudoarthrosis, limitation of spinal motion also affecting non-fused levels, back pain and disc degeneration in the non-fused spinal segments. Almost all of these complications can be avoided by the use of Apifix.”
“Now, there’s the ApiFix system,” said Ted Bird, sales chairman of ApiFex. “It is approved for sale in Europe. We are currently raising funding in order to fast-forward our sales-and-marketing efforts to launch a device that is designed to be a new standard for correcting scoliosis in adolescents.”